Swedish Pharma Co. Targets US Partner In Arbitration
The Swedish biopharmaceutical company Camurus AB is looking to terminate a licensing agreement with the opioid addiction drug company Braeburn Inc. to commercialize Camurus' drugs in North America, accusing the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article